Daniel J. Harrington

Daniel J. Harrington's AcademicInfluence.com Rankings

Religious Studies

#195

World Rank

#430

Historical Rank

#93

USA Rank

Theology

#314

World Rank

#690

Historical Rank

#133

USA Rank

religious-studies Degrees

Download Badge

Religious Studies

Why Is Daniel J. Harrington Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Daniel J. Harrington, S.J. , was an American academic and Jesuit priest who served as professor of New Testament and chair of the Biblical Studies department at Boston College School of Theology and Ministry .

(See a Problem?)

Daniel J. Harrington's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. (1998) (632)
Clinical and biologic implications of recurrent genomic aberrations in myeloma. (2003) (625)
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. (2002) (305)
Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. (2014) (260)
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. (2004) (258)
Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). (1987) (251)
Heart and Lung Transplants from HCV‐Infected Donors to Uninfected Recipients (2019) (216)
Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. (1988) (156)
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. (2010) (151)
Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy (2001) (134)
Understanding cancer patients’ experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey (2006) (127)
Patients' experiences with care for lung cancer and colorectal cancer: findings from the Cancer Care Outcomes Research and Surveillance Consortium. (2010) (123)
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma (1997) (104)
Pentostatin induces durable remissions in hairy cell leukemia. (1991) (98)
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. (2010) (92)
Representativeness of Participants in the Cancer Care Outcomes Research and Surveillance Consortium Relative to the Surveillance, Epidemiology, and End Results Program (2013) (84)
Patient perspectives on breast cancer treatment plan and summary documents in community oncology care (2013) (53)
The effect of intensive intermittent maintenance therapy in advanced low‐grade non‐Hodgkin's lymphoma (1987) (29)
Prognostic correlation of HLA‐DR expression in large cell lymphoma as determined by LN3 antibody staining. An eastern cooperative oncology group (ECOG) study (1990) (26)
Bayesian cure rate models for malignant melanoma: a case‐study of Eastern Cooperative Oncology Group trial E1690 (2002) (26)
The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer (2019) (23)
Phase II clinical trial of carboplatin in relapsed and refractory leukemia. (1992) (23)
Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis (2004) (22)
Escalating the intensity of postremission therapy improves the outcome in acute myeloid leukemia: The ECOG experience (1992) (22)
Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage ii aggressive histologic type non‐hodgkin's lymphoma (1988) (21)
Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group. (1992) (21)
Statistical and empirical evaluation of histopathologic reviews for quality assurance in the eastern cooperative oncology group (1988) (11)
Understanding Cancer Treatment and Outcomes (2004) (8)
Are we use of chemotherapy for elderly stage III colon cancer patients? An analysis from the Cancer Care Outcomes & Research Surveillance Consortium (CanCORS) (2008) (6)
Transplanting Thoracic Organs from Hepatitis C Positive Donors to Hepatitis C Uninfected Recipients (2018) (5)
Understanding Cancer Patients' Experience and Outcomes (2006) (5)
The impact of stroma on the discovery of molecular subtypes and prognostic gene signatures in serous ovarian cancer (2018) (4)
Quality assurance in cardiovascular and interventional radiology. (1992) (4)
A comparison between the Rappaport Classification and Working Formulation in cooperative group trials: the ECOG experience. (1992) (3)
Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group. (1990) (3)
Quality assurance of rectal cancer diagnosis and treatment - phase 3 : statistical methods to benchmark centres on a set of quality indicators (2011) (2)
Long-Term Outcomes in Heart and Lung Transplants from HCV-Viremic Donors to Uninfected Recipients: The Donate HCV Trial (2021) (1)
The Aftermath of Falsified Data in Breast Cancer Trials (1997) (1)
Evaluation of AJCC, UICC, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma (2013) (1)
Fulfillment of the uncertainty principle in cancer clinical trials. (2004) (0)
Preliminary ECOG analysis of treatment failure in primary operable breast cancer patients. (1991) (0)
Defining, identifying, and studying high-risk families: developing cohorts for epidemiologic study. (1995) (0)
Correlation Study of Volumetric Modulated Arc Therapy Plan Robustness With Local Failure for Head and Neck Cancer (2015) (0)
87. Heart and Lung Transplants From HCV-Viremic Donors to Uninfected Patients: Longer-Term Follow-Up (2019) (0)
Myeloma (mm) and the t(ll;14)(ql3;q32); increasing evidence for a biologically distinct subset of patients (2000) (0)
Cooperative Oncology Group Study 13) in Multiple Myeloma : An Eastern Δ 13 Abnormalities ( Hybridization Detection of Chromosome in Situ Fluorescence and Prognostic Significance of Interphase (2013) (0)
Deletions of 13ql4 in myeloma plasma cells usually represent large deletions of the q arm or monosomy (2000) (0)
Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease (2006) (0)

This paper list is powered by the following services:

Other Resources About Daniel J. Harrington

en.wikipedia.org

What Schools Are Affiliated With Daniel J. Harrington?

Daniel J. Harrington is affiliated with the following schools: